These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 18267248)
1. L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment. Cenci MA Parkinsonism Relat Disord; 2007; 13 Suppl 3():S263-7. PubMed ID: 18267248 [TBL] [Abstract][Full Text] [Related]
2. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244 [TBL] [Abstract][Full Text] [Related]
3. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease. Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628 [TBL] [Abstract][Full Text] [Related]
4. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Bezard E; Brotchie JM; Gross CE Nat Rev Neurosci; 2001 Aug; 2(8):577-88. PubMed ID: 11484001 [TBL] [Abstract][Full Text] [Related]
5. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677 [TBL] [Abstract][Full Text] [Related]
6. Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia. Cenci MA; Ohlin KE; Rylander D Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S59-63. PubMed ID: 20083009 [TBL] [Abstract][Full Text] [Related]
7. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Brotchie JM Mov Disord; 2005 Aug; 20(8):919-31. PubMed ID: 16007614 [TBL] [Abstract][Full Text] [Related]
8. Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. Cenci MA Amino Acids; 2002; 23(1-3):105-9. PubMed ID: 12373525 [TBL] [Abstract][Full Text] [Related]
9. The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease. Huot P; Johnston TH; Koprich JB; Fox SH; Brotchie JM Pharmacol Rev; 2013 Jan; 65(1):171-222. PubMed ID: 23319549 [TBL] [Abstract][Full Text] [Related]
10. Different functional basal ganglia subcircuits associated with anti-akinetic and dyskinesiogenic effects of antiparkinsonian therapies. Lacombe E; Khaindrava V; Melon C; Oueslati A; Kerkerian-Le Goff L; Salin P Neurobiol Dis; 2009 Oct; 36(1):116-25. PubMed ID: 19615446 [TBL] [Abstract][Full Text] [Related]
11. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease. Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479 [TBL] [Abstract][Full Text] [Related]